ML-193 N-(4-(N-(3,4-二甲基异恶唑-5-基)氨磺酰基)苯基)-6,8-二甲基-2-(吡啶-2-基)喹啉-4-甲酰胺

CAS 713121-80-3 MFCD13121803

化学结构图

713121-80-3
SMILES:

别名和识别编码

Chemical Name TranslationN-(4-(N-(3,4-二甲基异恶唑-5-基)氨磺酰基)苯基)-6,8-二甲基-2-(吡啶-2-基)喹啉-4-甲酰胺
Chemical NameML-193
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

相关文献及参考

  • [2]. Kotsikorou E, et, al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2013 Dec 31;52(52):9456-69.
  • [3]. Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33(1):15-21.
  • [4]. Hill JD, et, al. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol. 2018 Aug;175(16):3407-3421.
  • [1]. Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30.
  • [1]. Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30.
  • [2]. Kotsikorou E, et, al. Identification of the GPR55

系列性分类

  1. Medical Research Areas
  2. GPCR & G Protein
  3. GPR55  (G蛋白偶联受体55)

相关产品推荐